Altimmune, Inc. (NASDAQ:ALT) Q4 2025 Earnings Call Transcript March 5, 2026 Altimmune, Inc. misses on earnings expectations. Reported EPS is $-0.27191 EPS, expectations were $-0.25. Operator: Good ...
Altimmune (ALT) is advancing pemvidutide, a dual GLP-1/glucagon agonist, into a pivotal Phase 3 MASH trial in 2026.
Q4 2025 Earnings Call March 5, 2026 4:30 PM ESTCompany ParticipantsAllan Kells - Vice President of Investor RelationsSean Duffy ...
Omada Health (NASDAQ:OMDA) Q4 2025 Earnings Call Transcript March 6, 2026 Operator: Good day, and thank you for standing by. Welcome to the Omada Health Fourth Quarter 2025 Earnings Conference Call.
一些您可能无法访问的结果已被隐去。
显示无法访问的结果